sonidegib sonidegib sonidegib (inn), sold under the brand name odomzo, is a medication used to treat cancer. sonidegibclinical datatrade namesodomzoother nameslde225, erismodegibahfs/drugs.commonographmedlineplusa615034license data eu ema: by inn us dailymed: sonidegib pregnancycategory contraindicated (x) routes ofadministrationby mouthdrug classantineoplastic agentsatc codel01xj02 (who) legal statuslegal status au: s4 (prescription only) ca: ℞-only us: ℞-only eu: rx-only in general: ℞ (prescription only) pharmacokinetic databioavailability<10%protein binding>97%metabolismliver (cyp3a)elimination half-life~28 daysexcretionfeces (~70%), urine (30%)identifiers iupac name n-pyridin-3-yl]-2-methyl-3-benzamide cas number956697-53-3 ypubchem cid24775005drugbankdb09143chemspider25027390unii0rlu3vtk5mkeggd10119as salt: d10729chebichebi:90863 ychemblchembl2105737comptox dashboard (epa)dtxsid501009335 chemical and physical dataformulac26h26f3n3o3molar mass485.507 g·mol−13d model (jsmol)interactive image smiles c1cn(c(o1)c)c2=nc=c(c=c2)nc(=o)c3=cc=cc(=c3c)c4=cc=c(c=c4)oc(f)(f)f inchi inchi=1s/c26h26f3n3o3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17h,14-15h2,1-3h3,(h,31,33)/t16-,17+key:vzzjryrqspemtk-calchbbnsa-n sonidegib is hedgehog signaling pathway inhibitor (via smoothened antagonism). approvals and indications it was approved for medical use in the united states and in the european union in 2015 it is indicated for the treatment of adults with locally advanced basal-cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. pharmacology sonidegib is administered by mouth. common side effects include muscle spasms, hair loss, fatigue, abdominal pain, nausea, headache, and weight loss. sonidegib binds to and inhibits smoothened to inhibit activation of the hedgehog pathway. sonidegib is primarily metabolized by cyp3a and is eliminated hepatically. development it has been investigated as a potential treatment for: pancreatic cancer breast cancer basal cell carcinoma of the skin small cell lung cancer medulloblastoma advanced solid tumors (including ovarian, breast, pancreatic, stomach, oesophageal cancers and glioblastoma multiforme) acute leukemia and chronic myeloid leukemia myelofibrosis and essential thrombocythaemia it has demonstrated significant efficacy against melanoma in vitro and in vivo. it also demonstrated efficacy in a mouse model of pancreatic cancer.